HRP931410B1 - Process for the preparation of new finasteride - Google Patents

Process for the preparation of new finasteride

Info

Publication number
HRP931410B1
HRP931410B1 HR931410A HRP931410A HRP931410B1 HR P931410 B1 HRP931410 B1 HR P931410B1 HR 931410 A HR931410 A HR 931410A HR P931410 A HRP931410 A HR P931410A HR P931410 B1 HRP931410 B1 HR P931410B1
Authority
HR
Croatia
Prior art keywords
finasteride
magnesium halide
disclosed
new
preparation
Prior art date
Application number
HR931410A
Other languages
English (en)
Inventor
Ulf H Dolling
James A Mccauley
Richard J Varsolona
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26681536&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP931410(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of HRP931410A2 publication Critical patent/HRP931410A2/xx
Publication of HRP931410B1 publication Critical patent/HRP931410B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/003—Compounds containing elements of Groups 2 or 12 of the Periodic Table without C-Metal linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N5/00—Details of television systems
    • H04N5/74—Projection arrangements for image reproduction, e.g. using eidophor
    • H04N5/7416—Projection arrangements for image reproduction, e.g. using eidophor involving the use of a spatial light modulator, e.g. a light valve, controlled by a video signal
    • H04N5/7458—Projection arrangements for image reproduction, e.g. using eidophor involving the use of a spatial light modulator, e.g. a light valve, controlled by a video signal the modulator being an array of deformable mirrors, e.g. digital micromirror device [DMD]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Multimedia (AREA)
  • Signal Processing (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Confectionery (AREA)
  • Dental Preparations (AREA)
  • Seasonings (AREA)
HR931410A 1992-11-19 1993-11-18 Process for the preparation of new finasteride HRP931410B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97853592A 1992-11-19 1992-11-19
US08/010,734 US5468860A (en) 1992-11-19 1993-01-29 New finasteride processes

Publications (2)

Publication Number Publication Date
HRP931410A2 HRP931410A2 (en) 1996-06-30
HRP931410B1 true HRP931410B1 (en) 2000-06-30

Family

ID=26681536

Family Applications (2)

Application Number Title Priority Date Filing Date
HR931410A HRP931410B1 (en) 1992-11-19 1993-11-18 Process for the preparation of new finasteride
HR20000295A HRP20000295B1 (en) 1992-11-19 2000-05-12 Process for the preparation of a new finasteride

Family Applications After (1)

Application Number Title Priority Date Filing Date
HR20000295A HRP20000295B1 (en) 1992-11-19 2000-05-12 Process for the preparation of a new finasteride

Country Status (33)

Country Link
US (3) US5468860A (ro)
EP (3) EP0655458B1 (ro)
JP (2) JPH07110875B2 (ro)
CN (1) CN1058018C (ro)
AT (2) ATE164850T1 (ro)
AU (1) AU658774B2 (ro)
BG (2) BG62362B1 (ro)
CA (1) CA2103107C (ro)
CY (1) CY2135B1 (ro)
CZ (3) CZ287842B6 (ro)
DE (4) DE655458T1 (ro)
DK (2) DK0655458T3 (ro)
DZ (1) DZ1733A1 (ro)
ES (2) ES2052476T5 (ro)
FI (4) FI107450B (ro)
GR (4) GR940300045T1 (ro)
HK (1) HK1008338A1 (ro)
HR (2) HRP931410B1 (ro)
HU (2) HU216195B (ro)
IL (1) IL107574A (ro)
IS (2) IS1692B (ro)
LV (2) LV12212B (ro)
MX (1) MX9307222A (ro)
MY (2) MY110411A (ro)
NO (3) NO305912B1 (ro)
PH (1) PH31120A (ro)
RO (2) RO115165B1 (ro)
RU (1) RU2120445C1 (ro)
SI (1) SI9300603B (ro)
SK (2) SK286488B6 (ro)
TW (1) TW257766B (ro)
UA (1) UA41341C2 (ro)
WO (1) WO1994011387A2 (ro)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468860A (en) * 1992-11-19 1995-11-21 Merck & Co., Inc. New finasteride processes
IT1270660B (it) * 1994-10-13 1997-05-07 Poli Ind Chimica Spa Procedimento microbiologico per la preparazione di 3-oxo-4-azasteroidi-17beta-carbossi sostituiti e uso dei prodotti come inibitori dell'enzima 5alfa-riduttasi
US5670643A (en) * 1995-03-16 1997-09-23 Glaxo Wellcome Inc. Method for preparing finasteride
US5585383A (en) * 1995-05-03 1996-12-17 Merck & Co., Inc. Process for crystallizing a 4-azasteroid 5alpha-reductase inhibitor
JPH11512434A (ja) * 1995-09-15 1999-10-26 メルク エンド カンパニー インコーポレーテッド アンドロゲン過剰状態治療用の４−アザステロイド
GB2338234B (en) * 1998-06-10 2000-05-03 Torcan Chemical Ltd Preparation of finasteride
ES2153789B1 (es) * 1999-07-05 2001-10-16 Raga Consultores S L Procedimiento para la obtencion de 178-(n-terc-butlcarbamoil)-3-ona-4-aza-esteroides
AU773067B2 (en) * 1999-11-01 2004-05-13 Torcan Chemical Ltd. Production of polymorphic forms I and II of finasteride by complexation with group I or II metal salts
AU2001269911B2 (en) * 2000-09-07 2006-09-21 Dr. Reddy's Laboratories Ltd. Novel polymorphic form of 17-beta-(n-ter.butyl carbamoyl)-4-aza-5-alpha-androst-1-en-3-one and a process for preparing it
IL154785A0 (en) * 2000-09-07 2003-10-31 Reddys Lab Ltd Dr Polymorphic form of finasteride and processes for the preparation thereof
SK2732003A3 (en) * 2000-09-07 2004-01-08 Reddys Lab Ltd Dr Novel polymorphic form of 17-beta-(N-ter.butyl carbamoyl)-4-aza- 5-alpha-androst-1-en-3-one and a process for preparing it
KR100415858B1 (ko) * 2001-09-22 2004-01-24 한미약품 주식회사 17베타-(엔-3차-부틸카바모일)-3-온 스테로이드 화합물의제조방법
CN100428897C (zh) * 2002-08-16 2008-10-29 浙江寿峰堂生物工程有限公司 抗疲劳改善亚健康的保健食品及其制备方法
ES2206065B1 (es) * 2002-10-31 2005-08-16 Ragactives, S.L. Procedimiento para la obtencion de la forma polimorfica i de finasterida.
WO2004083230A1 (en) * 2003-03-19 2004-09-30 Hetero Drugs Limited Novel crystalline forms of finasteride
EP1651661B1 (en) * 2003-07-03 2008-08-27 Cipla Ltd. Process for the preparation of finasteride form i
US20050136015A1 (en) * 2003-12-17 2005-06-23 McKie Derrick B. Topical use of halosalicylic acid derivatives
US20070167477A1 (en) * 2006-01-13 2007-07-19 Mandava Venkata Naga Brahmeswa Processes to prepare finasteride polymorphs
US7531658B2 (en) * 2006-01-20 2009-05-12 Apotex Pharmachem Inc. Process for the preparation of 17-N-substituted-carbamoyl-4-aza-androst-1-en-3-ones
US7897800B2 (en) 2006-02-03 2011-03-01 Jr Chem, Llc Chemical compositions and methods of making them
US7687650B2 (en) 2006-02-03 2010-03-30 Jr Chem, Llc Chemical compositions and methods of making them
KR101324578B1 (ko) 2006-02-03 2013-11-01 제이알 켐, 엘엘씨 구리 및 아연 조성물을 사용하는 노화 방지 치료법
US7867522B2 (en) 2006-09-28 2011-01-11 Jr Chem, Llc Method of wound/burn healing using copper-zinc compositions
US20090076058A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched finasteride
US8273791B2 (en) 2008-01-04 2012-09-25 Jr Chem, Llc Compositions, kits and regimens for the treatment of skin, especially décolletage
CA2723398C (en) * 2008-05-05 2017-07-04 Abbott Gmbh & Co. Kg Method for evaluating the solubility of a crystalline substance in a polymer
US20160184354A1 (en) 2009-01-23 2016-06-30 Jr Chem, Llc Rosacea treatments and kits for performing them
US8952057B2 (en) 2011-01-11 2015-02-10 Jr Chem, Llc Compositions for anorectal use and methods for treating anorectal disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74365A (en) * 1984-02-27 1990-07-26 Merck & Co Inc 17beta-(n-t.-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one and pharmaceutical compositions containing it
US4760071A (en) * 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
EP0285383B1 (en) * 1987-04-03 1994-03-16 Merck & Co. Inc. Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones
NZ225100A (en) * 1987-06-29 1991-09-25 Merck & Co Inc Reaction of steroids (including 4-azasteroids) with a silylating agent in the presence of a quinone to introduce a delta' double bond and silylated intermediates
US5084574A (en) * 1988-04-18 1992-01-28 Merck & Co., Inc. Dehydrogenation process
US5237061A (en) * 1988-10-31 1993-08-17 Merck & Co., Inc. Methods of synthesizing benign prostatic hypertropic agents and their intermediates
US5021575A (en) 1989-11-13 1991-06-04 Merck & Co., Inc. Method for introducing a 1,2 double bond into azasteroids
JP3282731B2 (ja) * 1990-06-15 2002-05-20 メルク エンド カムパニー インコーポレーテッド 結晶の構造および大きさを改良する結晶化方法
EP0462662A3 (en) * 1990-06-20 1992-08-19 Merck & Co. Inc. 17beta-n-monosubstituted adamantyl/norbornanyl carbamoyl-4-aza-5alpha-androst-1-en-3-ones and androstan-3-ones
US5120847A (en) † 1990-08-27 1992-06-09 Merck & Co., Inc. Process for iodinating or brominating the α-methylenic carbon of a secondary amide
US5091534A (en) 1990-08-27 1992-02-25 Merck & Co., Inc. Trialkylsilyl trifluoromethanesulfonate mediated α-methylenic carbon functionalization of 4-AZA-5α-androstan-3-one steroids
US5061801A (en) * 1990-09-24 1991-10-29 Merck & Co., Inc. Intermediate for making 3-oxo-4-aza-androst-1-ene 17β-ketones
CA2050824A1 (en) * 1990-09-24 1992-03-25 John M. Williams Process for making 3-oxo-4-aza-androst-1-ene 17-.beta.-ketones
US5468860A (en) * 1992-11-19 1995-11-21 Merck & Co., Inc. New finasteride processes

Also Published As

Publication number Publication date
HRP931410A2 (en) 1996-06-30
DZ1733A1 (fr) 2002-02-17
IS1671B (is) 1997-12-19
TW257766B (ro) 1995-09-21
BG99637A (bg) 1996-04-30
FI20010289A (fi) 2001-02-15
DE69323754D1 (de) 1999-04-08
EP0823436A3 (en) 1998-11-25
CA2103107A1 (en) 1994-05-20
NO992580L (no) 1995-05-19
IL107574A (en) 2000-07-16
FI952422A0 (fi) 1995-05-18
GR940300045T1 (en) 1994-07-29
RO115164B1 (ro) 1999-11-30
CY2135B1 (en) 2002-05-21
LV12460B (en) 2000-09-20
CN1090583A (zh) 1994-08-10
DE69317856D1 (de) 1998-05-14
NO992580D0 (no) 1999-05-28
EP0599376A3 (en) 1994-09-28
FI107450B (fi) 2001-08-15
DE599376T1 (de) 1994-12-08
NO951986D0 (no) 1995-05-19
RO115165B1 (ro) 1999-11-30
JP2742409B2 (ja) 1998-04-22
SK281765B6 (sk) 2001-07-10
US5468860A (en) 1995-11-21
MY110411A (en) 1998-05-30
GR3026577T3 (en) 1998-07-31
ES2052476T3 (es) 1998-06-16
EP0655458B1 (en) 1999-03-03
CZ126895A3 (en) 1995-12-13
DE655458T1 (de) 1995-11-30
FI20010290A (fi) 2001-02-15
DE69323754T2 (de) 1999-10-07
EP0823436A2 (en) 1998-02-11
IL107574A0 (en) 1994-02-27
RU95112521A (ru) 1997-02-10
HU9303275D0 (en) 1994-03-28
FI952422A (fi) 1995-05-18
ES2052476T5 (es) 2008-11-01
EP0599376A2 (en) 1994-06-01
FI20040559A (fi) 2004-04-21
LV12212A (lv) 1999-01-20
UA41341C2 (uk) 2001-09-17
FI114215B (fi) 2004-09-15
CA2103107C (en) 2010-09-28
BG64464B1 (bg) 2005-03-31
DK0655458T3 (da) 1999-09-27
HUT66973A (en) 1995-01-30
NO307609B1 (no) 2000-05-02
EP0599376B1 (en) 1998-04-08
IS1692B (is) 1998-04-20
EP0655458A2 (en) 1995-05-31
GR3029554T3 (en) 1999-06-30
MY110410A (en) 1998-05-30
BG62362B1 (bg) 1999-09-30
NO951986L (no) 1995-05-19
LV12212B (en) 1999-03-20
JPH09235294A (ja) 1997-09-09
NO305912B1 (no) 1999-08-16
ATE177112T1 (de) 1999-03-15
DE69317856T2 (de) 1998-11-05
HRP20000295B1 (en) 2002-08-31
HU216195B (hu) 1999-05-28
AU658774B2 (en) 1995-04-27
WO1994011387A3 (en) 1994-09-29
EP0599376B2 (en) 2008-04-16
FI114800B (fi) 2004-12-31
FI116941B (fi) 2006-04-13
EP0655458A3 (en) 1996-07-10
MX9307222A (es) 1994-07-29
US5886184A (en) 1999-03-23
NO307888B1 (no) 2000-06-13
BG103170A (en) 1999-09-30
SI9300603B (sl) 2004-06-30
SI9300603A (en) 1994-06-30
HRP20000295A2 (en) 2000-08-31
IS4286A (is) 1994-05-20
WO1994011387A2 (en) 1994-05-26
LV12460A (lv) 2000-04-20
NO990468D0 (no) 1999-02-01
ES2052476T1 (es) 1994-07-16
PH31120A (en) 1998-02-23
HK1008338A1 (en) 1999-05-07
CZ301191B6 (cs) 2009-12-02
ATE164850T1 (de) 1998-04-15
JPH06199889A (ja) 1994-07-19
CN1058018C (zh) 2000-11-01
DK0599376T4 (da) 2008-07-28
HU210535A9 (en) 1995-04-28
ES2072848T3 (es) 1999-05-01
JPH07110875B2 (ja) 1995-11-29
RU2120445C1 (ru) 1998-10-20
GR950300043T1 (en) 1995-07-31
ES2072848T1 (es) 1995-08-01
AU5078793A (en) 1994-06-16
IS4094A (is) 1994-05-20
SK65995A3 (en) 1995-10-11
CZ301160B6 (cs) 2009-11-18
NO307888B3 (no) 2000-06-13
SK286488B6 (sk) 2008-11-06
NO990468L (no) 1995-05-19
US5652365A (en) 1997-07-29
CZ287842B6 (en) 2001-02-14

Similar Documents

Publication Publication Date Title
TW257766B (ro)

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
PNAN Change of the applicant name, address/residence

Owner name: MERCK SHARP & DOHME CORP., US

PNAN Change of the applicant name, address/residence

Owner name: SCHERING CORPORATION, US

ODRP Renewal fee for the maintenance of a patent

Payment date: 20121112

Year of fee payment: 20

PNAN Change of the applicant name, address/residence

Owner name: MERCK SHARP & DOHME CORP., US

PBON Lapse due to non-payment of renewal fee

Effective date: 20131119